Dermapharm Holding Se · XETR:DMP

Dermapharm — Q3 2023 Earnings Presentation

17 slides from Dermapharm's earnings presentation, Nov 15, 2023

1. Slide 1: Interim Statement Q3 2023

   Dermapharm Holding se INTERIM STATEMENT Q3 2023

2. Slide 2: Consolidated results at a glance

   DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 2 Consolidated results at a glance 9M 2023 9M 2022 Revenue EUR million 866.6 734.3 Adjusted EBITDA* EUR million 243.8 239.4 Adjusted EBITDA margin* % 28.1 32.6 Unadjusted EBITDA EUR million 208.4 231.9 Unadjusted EBITDA margin % 24.0 31.6 Operati

3. Slide 3: Financial Calendar 2024

   To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 3 Financial Calendar 2024 Publication of 2023 Annual Report 28 March 2024 Publication of Q1 Quar

4. Slide 4: Report on economic position: Revenue and earnings performance

   To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 4 REPORT ON ECONOMIC POSITION Revenue and earnings performance Revenue trend Year-on-year and 9M

5. Slide 5: Earnings before interest, tax, depreciation and amortisation (EBITDA)

   To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 5 Earnings before interest, tax, depreciation and amortisation (EBITDA) Year-on-year and 9M adju

6. Slide 6: Performance of the segments

   To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 6 Performance of the segments Branded pharmaceuticals 9M revenue trend by segment Revenue in the

7. Slide 7: 9M EBITDA trend by segment

   To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 7 9M EBITDA trend by segment1 Branded pharmaceuticals EUR The adjusted EBITDA amounted to EUR 18

8. Slide 8: Report on expected developments

   To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 8 REPORT ON EXPECTED DEVELOPMENTS Given that the Company’s performance in the first nine months

9. Slide 9: Interim consolidated financial statements: statement of financial position

   To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 9 INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT 30 SEPTEMBER 2023 Rounding differences may ari

10. Slide 10: Equity and liabilities

    To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 10 Equity and liabilities EUR thousand 30 September 2023 31 December 2022 Equity Issued capital

11. Slide 11: Condensed statement of comprehensive income

    To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 11 Condensed statement of comprehensive income 9 months ended EUR thousand 30 September 2023 30

12. Slide 12: Other comprehensive income

    To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 12 9 months ended EUR thousand 30 September 2023 30 September 2022 Other comprehensive income no

13. Slide 13: Condensed statement of cash flows

    To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 13 Condensed statement of cash flows 9 months ended EUR thousand 30 September 2023 30 September

14. Slide 14: Cash flows from financing activities

    To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 14 9 months ended EUR thousand 30 September 2023 30 September 2022 Dividends paid – 56,532 – 116

15. Slide 15: Segment reporting

    To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 15 Segment reporting Reconciliation/ Branded pharmaceuticals* Other healthcare products** Parall

16. Slide 16: Imprint

    To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q3 2023 16 IMPRINT Publisher Concept, editing, layout and typesetting Dermapharm Holding SE SPARKS CONSU

17. Slide 17: Dermapharm Holding SE contact details

    Dermapharm Holding SE Lil-Dagover-Ring 7 82031 Grünwald Germany Telefon: +49 (89) 6 41 86 – 0 E-Mail: ir@dermapharm.com https://ir.dermapharm.de

Dermapharm Holding — Q3 2023 Earnings Presentation on 6ix